Exhibit 99.1
Anika Therapeutics Reports Record Second-Quarter Revenue and Earnings
Net Income Grows 58% and EPS Rise to $0.40
CingalTM Phase III Osteoarthritis Clinical Study in Active Patient Recruitment Stage
BEDFORD, Mass.--(BUSINESS WIRE)--July 31, 2013--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today reported financial results for the quarter ended June 30, 2013.
Management Commentary
“Anika delivered the strong results we expected in the second quarter of 2013,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “Total revenue grew 6% from the second quarter last year, driven by robust Orthobiologics product demand. We are also very pleased with achieving a record second quarter net income, which represents a 58% increase from the same period last year. Our consistent delivery of product revenue growth and planned business improvements has enabled us to drive bottom line growth and generate robust cash flow.”
“This was another strong quarter for our flagship product, Orthovisc®, both domestically and internationally,” continued Sherwood. “Orthovisc continues to bring differentiated clinical benefits to physicians and patients. Our U.S. distribution partner Depuy Mitek is executing on a strategic sales and marketing plan to support patient care and enhance physician office efficiency. The growth in our U.S. Orthovisc revenue indicates these efforts continue to have a positive impact on product demand.”
“Anika is well-positioned for continued growth and profitability improvement in the second half of 2013,” said Sherwood. “Our viscosupplementation business is strong, and we are driving efficiencies in our operations and manufacturing. We are also enthusiastic about our product pipeline. Cingal, our third generation viscosupplementation product, is a single-injection osteoarthritis treatment which includes a therapeutic anti-inflammatory agent. During the second quarter, we commenced a multinational Phase III clinical study in support of our CE Mark application for Cingal. Launching this trial is an important step forward in our pipeline development strategy, and we look forward to bringing Cingal into the market.”
Revenue
For the second quarter of 2013, total revenue grew 6.1% to $20.8 million, from $19.6 million a year earlier. The company’s revenue growth was primarily driven by increased viscosupplementation product revenue, in particular domestic sales of Orthovisc.
Product Gross Margin
Product gross margin for the second quarter of 2013 improved to 68.5%, from 57.2% in the second quarter last year. The improvement for the quarter was driven by manufacturing facilities consolidation, realization of operational efficiencies, more favorable product mix, as well as the elimination of the non-profitable tissue engineering operations since the beginning of 2013.
Operating Expenses
Research and development expenses for the second quarter of 2013 increased 40.9% from the second quarter of 2012. The increase reflected expenses for the company’s Cingal clinical trial and other planned product pipeline initiatives. Selling, general and administrative (“SG&A”) expenses in the second quarter of 2013 decreased by 17.2% from the same period last year. The decline in SG&A was primarily driven by the company’s ongoing cost reduction initiatives.
Operating and Net Income
Operating income for the second quarter of 2013 grew to $9.4 million, from $6.1 million in the same period in 2012. Net income increased to $5.9 million, or $0.40 per diluted share, from $3.7 million, or $0.26 per diluted share, in the second quarter last year. The growth in operating income, net income and earnings per share was primarily driven by improvement in product gross profit.
Cash and Cash Equivalents
Anika’s cash and cash equivalents at June 30, 2013 increased to $54.1 million, from $44.1 million at December 31, 2012, driven primarily by higher income from operations, increased cash collections on accounts receivable and option exercises during the first half of 2013.
Conference Call Information
Anika will hold a conference call to discuss its financial results, business highlights and outlook tomorrow, Thursday, August 1, 2013 at 9:00 a.m. ET. In addition, the company will answer questions concerning business and financial developments and trends, regulatory activity related to Monovisc, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
To listen to the conference call, dial 877-546-5019 (international callers dial 857-244-7551) and use the passcode 16226176. Please call approximately 10 minutes before the starting time and reference Anika Therapeutics. In addition, the conference call will be available through a live audio webcast in the “Investor Relations” section of the Anika Therapeutics website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The conference call will be archived and accessible on the same website shortly after the conclusion of the call.
About Anika Therapeutics, Inc.
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika’s products range from orthopedic/joint health solutions led by Orthovisc®, a treatment for osteoarthritis of the knee; to surgical aids in the anti-adhesion and ophthalmic fields. The company also offers aesthetic dermal fillers for the correction of facial wrinkles. Anika’s Italian subsidiary, Anika S.r.l., provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in areas such as advanced wound treatment and ear, nose and throat care. Its regenerative technology advances Anika’s vision to offer therapeutic products and medical solutions that go beyond pain relief to protect and restore damaged tissue.
The statements made in this press release which are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to (i) future demand for Orthovisc, (ii) the company’s plans to continue to drive efficiencies in operations and manufacturing, (iii) the prospects for the company’s product pipeline, (iv) bringing Cingal to market, (v) expectations for future growth and profitability improvement in the second half of 2013,and (vi) expectations regarding, research and development spending, selling, general and administrative spending, and product gross margin. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks, uncertainties and other factors. The company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors including (i) the company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all, obtain pre-clinical or clinical data to support a pre-market approval application or 510(k) application, or timely file and receive FDA or other regulatory approvals or clearances of its products, or that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (ii) the company's research and product development efforts and their relative success, including whether the company has any meaningful sales of any new products resulting from such efforts; (iii) the cost effectiveness and efficiency of our clinical studies, manufacturing operations and production planning; (iv) the strength of the economies in which the company operates or will be operating, as well as the political stability of any of those geographic areas; (v) future determinations by the company to allocate resources to products and in directions not presently contemplated, (vi) the company’s ability to launch Monovisc in the U.S., if at all; (vii) the company’s ability to provide an adequate and timely supply of its ophthalmic, Orthovisc and other products to its customers, (viii) our ability to successfully manage and turnaround Anika S.r.l.’s business, and (ix) the company’s ability to achieve its stated growth targets. Certain other factors that might cause the company's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's Annual Report on Form 10-K for the year ended December 31, 2012, as well as those described in the company's other press releases and SEC filings.
| Anika Therapeutics, Inc. and Subsidiaries |
| Condensed Consolidated Statements of Operations |
| (unaudited) |
| | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| | 2013 | | 2012 | | 2013 | | 2012 |
| Product revenue | | $ | 20,067,407 | | | $ | 18,882,277 | | | $ | 34,561,896 | | | $ | 32,495,605 | |
| Licensing, milestone and contract revenue | | | 760,970 | | | | 742,492 | | | | 1,513,492 | | | | 1,489,824 | |
| Total revenue | | | 20,828,377 | | | | 19,624,769 | | | | 36,075,388 | | | | 33,985,429 | |
| | | | | | | | |
| Operating expenses: | | | | | | | | |
| Cost of product revenue | | | 6,311,332 | | | | 8,084,226 | | | | 11,152,502 | | | | 14,497,707 | |
| Research & development | | | 1,829,052 | | | | 1,298,170 | | | | 3,411,962 | | | | 2,831,273 | |
| Selling, general & administrative | | | 3,400,679 | | | | 4,108,503 | | | | 7,347,793 | | | | 7,459,519 | |
| Restructuring charges | | | (111,178 | ) | | | - | | | | (246,785 | ) | | | - | |
| Total operating expenses | | | 11,429,885 | | | | 13,490,899 | | | | 21,665,472 | | | | 24,788,499 | |
| Income from operations | | | 9,398,492 | | | | 6,133,870 | | | | 14,409,916 | | | | 9,196,930 | |
| Interest income (expense), net | | | (36,381 | ) | | | (49,129 | ) | | | (75,939 | ) | | | (100,332 | ) |
| Income before income taxes | | | 9,362,111 | | | | 6,084,741 | | | | 14,333,977 | | | | 9,096,598 | |
| Provision for income taxes | | | 3,467,219 | | | | 2,347,873 | | | | 5,371,083 | | | | 3,447,611 | |
| Net income | | $ | 5,894,892 | | | $ | 3,736,868 | | | $ | 8,962,894 | | | $ | 5,648,987 | |
| | | | | | | | |
| Basic net income per share: | | | | | | | | |
| Net income | | $ | 0.44 | | | $ | 0.28 | | | $ | 0.67 | | | $ | 0.43 | |
| Basic weighted average common shares outstanding | | | 13,510,573 | | | | 13,262,023 | | | | 13,459,049 | | | | 13,212,424 | |
| Diluted net income per share: | | | | | | | | |
| Net income | | $ | 0.40 | | | $ | 0.26 | | | $ | 0.62 | | | $ | 0.39 | |
| Diluted weighted average common shares outstanding | | | 14,578,927 | | | | 14,443,794 | | | | 14,484,978 | | | | 14,302,439 | |
| | | | | | | | |
| Anika Therapeutics, Inc. and Subsidiaries |
| Condensed Consolidated Balance Sheets |
| (unaudited) |
| | | | |
| | June 30, | | December 31, |
| ASSETS | | 2013 | | 2012 |
| Current assets: | | | | |
| Cash and cash equivalents | | $ | 54,140,459 | | | $ | 44,067,477 | |
| Accounts receivable, net of reserves of $332,148 and $337,459 at June 30, 2013 and December 31, 2012, respectively | | | 19,065,386 | | | | 21,462,481 | |
| Inventories | | | 10,357,798 | | | | 8,283,472 | |
| Current portion deferred income taxes | | | 1,989,422 | | | | 2,031,583 | |
| Prepaid expenses and other | | | 920,873 | | | | 1,539,477 | |
| Total current assets | | | 86,473,938 | | | | 77,384,490 | |
| Property and equipment, at cost | | | 51,618,726 | | | | 52,376,013 | |
| Less: accumulated depreciation | | | (17,772,147 | ) | | | (17,263,032 | ) |
| | | 33,846,579 | | | | 35,112,981 | |
| Long-term deposits and other | | | 154,050 | | | | 171,053 | |
| Intangible assets, net | | | 18,996,886 | | | | 20,334,636 | |
| Goodwill | | | 8,923,197 | | | | 9,065,891 | |
| Total Assets | | $ | 148,394,650 | | | $ | 142,069,051 | |
| | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | |
| Current liabilities: | | | | |
| Accounts payable | | $ | 2,699,678 | | | $ | 2,341,838 | |
| Accrued expenses | | | 4,503,551 | | | | 5,837,044 | |
| Deferred revenue | | | 1,527,917 | | | | 2,875,067 | |
| Current portion of long-term debt | | | 1,600,000 | | | | 1,600,000 | |
| Income taxes payable | | | 1,370,172 | | | | 1,798,669 | |
| Total current liabilities | | | 11,701,318 | | | | 14,452,618 | |
| Other long-term liabilities | | | 1,264,427 | | | | 1,541,124 | |
| Long-term deferred revenue | | | 2,069,444 | | | | 2,152,778 | |
| Deferred tax liability | | | 6,725,622 | | | | 6,997,397 | |
| Long-term debt | | | 7,200,000 | | | | 8,000,000 | |
| Commitments and contingencies | | | - | | | | - | |
| Stockholders’ equity: | | | | |
Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively | | | - | | | | - | |
Common stock, $.01 par value; 30,000,000 shares authorized, 14,017,280 and 13,866,060 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively | | | 140,173 | | | | 138,659 | |
| Additional paid-in-capital | | | 67,385,076 | | | | 65,431,424 | |
| Accumulated currency translation adjustment | | | (3,063,985 | ) | | | (2,654,630 | ) |
| Retained earnings | | | 54,972,575 | | | | 46,009,681 | |
| Total stockholders’ equity | | | 119,433,839 | | | | 108,925,134 | |
| Total Liabilities and Stockholders’ Equity | | $ | 148,394,650 | | | $ | 142,069,051 | |
| | | | |
| Anika Therapeutics, Inc. and Subsidiaries |
| Supplemental Financial Data |
| Revenue by Product Line and Product Gross Margin |
| (unaudited) |
| | | | | | |
| | Three Months Ended June 30, |
| | 2013 | | 2012 | | % Change |
| Orthobiologics | | $ | 16,506,226 | | | $ | 10,903,364 | | | 51 | % |
| Dermal | | | 557,059 | | | | 155,735 | | | 258 | % |
| Surgical | | | 1,830,022 | | | | 1,464,505 | | | 25 | % |
| Opthalmic | | | 464,340 | | | | 5,299,732 | | | (91 | %) |
| Veterinary | | | 709,760 | | | | 1,058,941 | | | (33 | %) |
| Total Product Revenue | | $ | 20,067,407 | | | $ | 18,882,277 | | | 6 | % |
| | | | | | |
| Product gross profit | | $ | 13,756,075 | | | $ | 10,798,051 | | | |
| Product gross margin | | | 68.5 | % | | | 57.2 | % | | |
| | | | | | |
| | | | | | |
| | Six Months Ended June 30, |
| | 2013 | | 2012 | | % Change |
| Orthobiologics | | $ | 27,789,773 | | | $ | 21,020,209 | | | 32 | % |
| Dermal | | | 798,643 | | | | 657,051 | | | 22 | % |
| Surgical | | | 2,818,886 | | | | 2,448,133 | | | 15 | % |
| Opthalmic | | | 1,392,798 | | | | 6,623,726 | | | (79 | %) |
| Veterinary | | | 1,761,796 | | | | 1,746,486 | | | 1 | % |
| Total Product Revenue | | $ | 34,561,896 | | | $ | 32,495,605 | | | 6 | % |
| | | | | | |
| Product gross profit | | $ | 23,409,394 | | | $ | 17,997,898 | | | |
| Product gross margin | | | 67.7 | % | | | 55.4 | % | | |
| | | | | | |
| | | | | | |
| | | | | | |
| Anika Therapeutics, Inc. and Subsidiaries |
| Supplemental Financial Data |
| Revenue by Geographic Region |
| (unaudited) |
| | | | | | |
| | Three Months Ended June 30, |
| | 2013 | | 2012 | | % Change |
| United States | | $ | 14,765,402 | | | $ | 16,011,667 | | | (8 | %) |
| Europe | | | 1,941,891 | | | | 1,521,552 | | | 28 | % |
| Other | | | 3,360,114 | | | | 1,349,058 | | | 149 | % |
| Total | | $ | 20,067,407 | | | $ | 18,882,277 | | | 6 | % |
| | | | | | |
| | | | | | |
| | Six Months Ended June 30, |
| | 2013 | | 2012 | | % Change |
| United States | | $ | 26,332,181 | | | $ | 26,401,712 | | | (0 | %) |
| Europe | | | 3,489,805 | | | | 3,677,281 | | | (5 | %) |
| Other | | | 4,739,910 | | | | 2,416,612 | | | 96 | % |
| Total | | $ | 34,561,896 | | | $ | 32,495,605 | | | 6 | % |
CONTACT:
Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., 781-457-9000
CEO
or
Sylvia Cheung, 781-457-9000
CFO
